Fyodor Urnov

Oct 18, 2024 | liebertpub.com | Suchita P. Nety |Fyodor Urnov |Jon Rueda |Lluis Montoliu

The CRISPR JournalEditor-in-Chief: Rodolphe Barrangou, PhDISSN: 2573-1599 Online ISSN: 2573-1602 Published BimonthlyCurrent Volume: 7 Journal Impact Factor: 3.8* *2023 Journal Citation Reports™ (Clarivate, 2024) The only peer-reviewed journal dedicated to the science and applications of gene editing.

Aug 12, 2024 | msn.com | Fyodor Urnov

Continue reading More for You   Continue reading More for You

Aug 12, 2024 | yahoo.com | Fyodor Urnov

Credit - Getty ImagesAfter a lifetime in the field of epigenetics, and nearly 20 years after my colleagues and I coined the term “genome editing,” I will be the first to admit that describing the “epigenome”—a marvelous biological process that guides what our genes do—takes a bit of explaining. I find that thinking about the genome and epigenome in terms of music and sound-mixing can be helpful here. We experience all sorts of music as we go through life, from Bach and Brahms to Laufey and Lizzo.

Jul 17, 2024 | nature.com | Melinda Kliegman |Jonathan H. Esensten |Ross Wilson |Fyodor Urnov

AbstractNineteen genetic therapies have been approved by the U.S. Food and Drug Administration (FDA) to date, a number that now includes the first CRISPR genome editing therapy for sickle cell disease, CASGEVY (exagamglogene autotemcel). This extraordinary milestone is widely celebrated because of the promise for future genome editing treatments of previously intractable genetic disorders and cancers.